Vaccine Cost Effectiveness: Interactive Pneumococcal Vaccination Policy Model
Vaccination of children in developing countries against pneumococcal infection has great potential to save lives and reduce disability. The pneumococcus (Streptococcus pneumoniae) is the leading bacterial cause of acute lower respiratory infections, which in turn, are a major cause of child mortality. It also causes meningitis, other forms of invasive bacterial disease, and ear infections (Otitis Media).
The economic burden caused by pneumococcal infection can be great and can be felt on the family, health system, and national level. Routine vaccination of infants against pneumococcus needs substantial investment by governments, non-governmental organizations, and donors.
Development of the Model
The Interactive Pneumococcal Conjugate Vaccination Policy Model was developed by infectious disease specialists, computer scientists and decision analysts based at the University of Medicine and Dentistry of New Jersey, in collaboration with the Department of International Health at Johns Hopkins Bloomberg School of Public Health. The model underwent an extensive expert review process, drawing on experts in the fields of pneumococcal epidemiology and disease burden, penumococcal conjugate vaccinology, health economics, and policy.
Using the Model
This Interactive Pneumococcal Conjugate Vaccination Policy Model allows the health benefits, costs, and cost-effectiveness of childhood pneumococcal conjugate vaccine to be projected according to an evidence-based approach. It is designed for users with familiarity using personal computers but with limited experience conducting health economic analyses. Wherever possible, the model is pre-populated with inputs drawn from the highest quality data sources.
This model addresses the need for streamlined cost-effectiveness analysis tools to assist decision makers in understanding the economic and health benefits associated with vaccine introductions.
This Interactive Pneumococcal Vaccination Policy Model was developed through an expert panel process. The panel reached consensus on the key assumptions about epidemiology, vaccine efficacy, costs and model outputs projecting the cost-effectiveness of pneumococcal conjugate vaccine for infants in GAVI-eligible countries. Members of the panel were chosen for their expertise in pneumococcal epidemiology, vaccine-related health economics, public health, and/or preventive medicine in GAVI-eligible settings.
To login and begin using the model now, click here.